Pharmacokinetics of alendronate: an overview.

@article{Lin1999PharmacokineticsOA,
  title={Pharmacokinetics of alendronate: an overview.},
  author={Jiunn Huei Lin and Greg Russell and Beate Gertz},
  journal={International journal of clinical practice. Supplement},
  year={1999},
  volume={101},
  pages={18-26}
}
Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate, MK-217, Fosamax), an aminobisphosphonate, is a potent inhibitor of osteoclast-mediated bone resorption and is used for the treatment of bone disorders, osteoporosis and Pagets disease of bone. Alendronate, like all bisphosphonates, is absorbed poorly in animals and humans; oral bioavailability is less than 2% in all species studied, including humans. Systemically available alendronate disappears very rapidly from plasma, and the drug… CONTINUE READING